DRR168524
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- ANDROGEN_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- OXIDATIVE_PHOSPHORYLATION+0.390
- CHOLESTEROL_HOMEOSTASIS+0.360
- PROTEIN_SECRETION+0.320
- MTORC1_SIGNALING+0.270
- IL6_JAK_STAT3_SIGNALING+0.260
- ADIPOGENESIS+0.250
- HYPOXIA+0.250
Top 10 suppressed
- E2F_TARGETS-0.410
- WNT_BETA_CATENIN_SIGNALING-0.380
- G2M_CHECKPOINT-0.300
- MYC_TARGETS_V2-0.300
- DNA_REPAIR-0.190
- MITOTIC_SPINDLE-0.100
- PANCREAS_BETA_CELLS-0.080
- BILE_ACID_METABOLISM-0.070
- MYOGENESIS-0.070
- SPERMATOGENESIS-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_49852ZBH | pilocytic astrocytoma | — | 0.835 |
| 2 | SRR33346941 | — | — | 0.819 |
| 3 | DRR168598 | — | — | 0.811 |
| 4 | BS_SDZY6RZ3 | pilocytic astrocytoma | — | 0.801 |
| 5 | BS_T1W4JA94 | pilocytic astrocytoma | — | 0.792 |
| 6 | BS_HV8PFRBR | pilocytic astrocytoma | — | 0.788 |
| 7 | BS_7Z93ZYMS | pilocytic astrocytoma | — | 0.782 |
| 8 | BS_ZZMYDZJW | pilocytic astrocytoma | — | 0.781 |
| 9 | BS_6N3AFF66 | pilocytic astrocytoma | — | 0.774 |
| 10 | BS_3W07B2TG | subependymal giant cell astrocytoma(SEGA) | — | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |